Why Viridian Therapeutics (VRDN) Shares Are Trading Higher Today - Viridian Therapeutics (NASDAQ:VRDN)

Viridian Therapeutics Inc VRDN announced topline clinical data from the third, low-dose cohort in its ongoing Phase 1/2 trial of VRDN-001 for active thyroid eye disease (TED).
VRDN-001 was evaluated at 3, 10, and 20 mg/kg doses. The company previously announced positive results from the first two dose cohorts, demonstrating a favorable safety profile.
The third cohort evaluated a VRDN-001 dose of 3 mg/kg with 6-week data.
Related: Viridian Therapeutics' Lead Product Has An Opportunity To Differentiate, Analyst, Sees 85% Upside.
Among 3 mg/kg VRDN-001 treated patients, 67% were proptosis (bulging eyes) responders, 56% were overall responders, 67% achieved a Clinical Activity Score (CAS) of 0 or 1, and 20% had complete resolution of their diplopia (double vision).
Across all 21 VRDN-001 treated patients to date, 71% were proptosis responders, 67% were overall responders, 62% achieved a CAS of 0 or 1, and 54% had complete resolution of their diplopia, with a favorable safety profile seen across all dose levels –
3 mg/kg data support planned once-monthly low-volume subcutaneous dosing profile for VRDN-002 and VRDN-003.
Price Action: VRDN shares are up 11.60% at $30.64 on the last check Monday.

Viridian's Thyroid Eye Disease Candidate Shows Promise At Lower Doses